ERBB2 and neoplasm: Such addition was the outcome of the beneficial effects that Tmab has proven to have for women with HER2+ MBC and EBC when it is administered with chemotherapy, slowing down tumor progression, inducing tumor regression, and increasing patients’ overall survival rate [28].